Result Status: Final

Lab

Status

## Labcorp

Result Name

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

General Comments and Additional Information

Fasting: No Total Vol: Source:

Flag

163600 Lyme, Line Blot, Serum				
Lyme IgG Line Blot Interp.	Negative	Negative	Final	01
IgG P93 Ab.	Absent		Final	01
IgG P66 Ab.	Absent		Final	01
IgG P58 Ab.	Present		Final	01
IgG P45 Ab.	Absent		Final	01
IgG P41 Ab.	Present		Final	01
IgG P39 Ab.	Absent		Final	01
IgG P30 Ab.	Absent		Final	01
IgG P28 Ab.	Absent		Final	01
IgG P23 Ab.	Absent		Final	01
IgG P18 Ab.	Absent		Final	01
Lyme IgM Line Blot Interp.	Negative	Negative	Final	01

Result

Range/Units

Please Note: Lyme immunoblot alone is not recommended for the diagnosis of Lyme disease. Current guidelines recommend the use of a two-tiered approach to Lyme serology testing to improve the sensitivity and specificity of testing. Labcorp offers test code 164226 Lyme Disease Serology with Reflex to aid in the diagnosis of Lyme Disease.

Result Status: Final

## Labcorp

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Received Date/Time:

Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
IgM P41 Ab.		Absent		Final	01
IgM P39 Ab.		Absent		Final	01
IgM P23 Ab.		Absent		Final	01
Additional Information:				Final	01

Per CDC criteria, the Lyme IgG Immunoblot is interpreted as positive if IgG-class antibodies are detected to 5 or more B. burgdorferi proteins, and the Lyme IgM Immunoblot is interpreted as positive if IgM-class antibodies are detected to 2 or more B. burgdorferi proteins. Immunoblot patterns not meeting these criteria should not be interpreted as positive. Epitopes from certain B. burgdorferi proteins (e.g., p41) are conserved across other bacteria, which may lead to the detection of IgM-and/or IgG class antibodies on the Lyme disease immunoblots in patients without Lyme disease. Immunoblot should only be ordered on specimens that are positive or equivocal by an FDA-licensed Lyme disease antibody screening test (e.g., EIA).

Results of the Lyme IgM immunoblot should not be considered in patients with 30 or more days of symptoms.